Cargando…

Cas9-derived peptides presented by MHC Class II that elicit proliferation of CD4(+) T-cells

CRISPR–Cas9 mediated genome editing offers unprecedented opportunities for treating human diseases. There are several reports that demonstrate pre-existing immune responses to Cas9 which may have implications for clinical development of CRISPR-Cas9 mediated gene therapy. Here we use 209 overlapping...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simhadri, Vijaya L., Hopkins, Louis, McGill, Joseph R., Duke, Brian R., Mukherjee, Swati, Zhang, Kate, Sauna, Zuben E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384835/ https://www.ncbi.nlm.nih.gov/pubmed/34429421 http://dx.doi.org/10.1038/s41467-021-25414-9

Ejemplares similares

HLA Variants and Inhibitor Development in Hemophilia A: A Retrospective Case-Controlled Study Using the ATHNdataset
por: McGill, Joseph R., et al.
Publicado: (2021)

Prevalence of Pre-existing Antibodies to CRISPR-Associated Nuclease Cas9 in the USA Population
por: Simhadri, Vijaya L., et al.
Publicado: (2018)

A structural homology approach to identify potential cross-reactive antibody responses following SARS-CoV-2 infection
por: McGill, Joseph R., et al.
Publicado: (2022)

The MHC Associated Peptide Proteomics assay is a useful tool for the non-clinical assessment of immunogenicity
por: Jankowski, Wojciech, et al.
Publicado: (2023)

SampPick: Selection of a Cohort of Subjects Matching a Population HLA Distribution
por: McGill, Joseph R., et al.
Publicado: (2019)

Recent advances in (therapeutic protein) drug development
por: Lagassé, H.A. Daniel, et al.
Publicado: (2017)

Polymorphisms in the F8 Gene and MHC-II Variants as Risk Factors for the Development of Inhibitory Anti-Factor VIII Antibodies during the Treatment of Hemophilia A: A Computational Assessment
por: Pandey, Gouri Shankar, et al.
Publicado: (2013)

Mathematical model of a personalized neoantigen cancer vaccine and the human immune system
por: Rodriguez Messan, Marisabel, et al.
Publicado: (2021)

Further Evidence That MicroRNAs Can Play a Role in Hemophilia A Disease Manifestation: F8 Gene Downregulation by miR-19b-3p and miR-186-5p
por: Jankowska, Katarzyna I., et al.
Publicado: (2020)

Small ncRNA Expression-Profiling of Blood from Hemophilia A Patients Identifies miR-1246 as a Potential Regulator of Factor 8 Gene
por: Sarachana, Tewarit, et al.
Publicado: (2015)

Non-conventional sources of peptides presented by MHC class I
por: Starck, Shelley R., et al.
Publicado: (2011)

The MHC class I peptide repertoire is molded by the transcriptome
por: Fortier, Marie-Hélène, et al.
Publicado: (2008)

Motifs and supermotifs for MHC class II binding peptides
Publicado: (1995)

Efficient Propagation of Circulating Tumor Cells: A First Step for Probing Tumor Metastasis
por: Xiao, Jerry, et al.
Publicado: (2020)

Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus
por: Hernandez, Nancy E., et al.
Publicado: (2023)

Corrigendum to “Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus” [Heliyon 9(4) (April 2023) e15032]
por: Hernandez, Nancy E., et al.
Publicado: (2023)

Model for the Peptide-Free Conformation of Class II MHC Proteins
por: Painter, Corrie A., et al.
Publicado: (2008)

Prediction of MHC class I binding peptides, using SVMHC
por: Dönnes, Pierre, et al.
Publicado: (2002)

Regulation of MHC Class II-Peptide Complex Expression by Ubiquitination
por: Cho, Kyung-Jin, et al.
Publicado: (2013)

Properties of MHC Class I Presented Peptides That Enhance Immunogenicity
por: Calis, Jorg J. A., et al.
Publicado: (2013)

A Peptide Filtering Relation Quantifies MHC Class I Peptide Optimization
por: Dalchau, Neil, et al.
Publicado: (2011)

Factor VIII-Fc Activates Natural Killer Cells via Fc-Mediated Interactions With CD16
por: Lagassé, H.A. Daniel, et al.
Publicado: (2021)

Dynamically Driven Allostery in MHC Proteins: Peptide-Dependent Tuning of Class I MHC Global Flexibility
por: Ayres, Cory M., et al.
Publicado: (2019)

CapsNet-MHC predicts peptide-MHC class I binding based on capsule neural networks
por: Kalemati, Mahmood, et al.
Publicado: (2023)

Peptide length significantly influences in vitro affinity for MHC class II molecules
por: O'Brien, Cathal, et al.
Publicado: (2008)

Modified aptamers as reagents to characterize recombinant human erythropoietin products
por: Jankowski, Wojciech, et al.
Publicado: (2020)

Improving peptide-MHC class I binding prediction for unbalanced datasets
por: Sales, Ana Paula, et al.
Publicado: (2008)

Identical peptides recognized by MHC class I- and II-restricted T cells
Publicado: (1989)

Class I MHC can present an endogenous peptide to cytotoxic T lymphocytes
Publicado: (1989)

ER stress affects processing of MHC class I-associated peptides
por: Granados, Diana P, et al.
Publicado: (2009)

Design of Peptide Immunotherapies for MHC Class-II-Associated Autoimmune Disorders
por: Fridkis-Hareli, Masha
Publicado: (2013)

The Utility of Supertype Clustering in Prediction for Class II MHC-Peptide Binding
por: Shen, Wen-Jun, et al.
Publicado: (2018)

A Missing Switch in Peptide Exchange for MHC Class II Molecules
por: Freund, Christian, et al.
Publicado: (2019)

From Recoding to Peptides for MHC Class I Immune Display: Enriching Viral Expression, Virus Vulnerability and Virus Evasion
por: Atkins, John F., et al.
Publicado: (2021)

Organizing MHC Class II Presentation
por: Fooksman, David R.
Publicado: (2014)

A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants
por: Pishesha, Novalia, et al.
Publicado: (2021)

TAPBPR alters MHC class I peptide presentation by functioning as a peptide exchange catalyst
por: Hermann, Clemens, et al.
Publicado: (2015)

Rapid peptide exchange on MHC class I by small molecules elucidates dynamics of bound peptide
por: Hadeler, Andries, et al.
Publicado: (2022)

The impact of DM on MHC class II–restricted antigen presentation can be altered by manipulation of MHC–peptide kinetic stability
por: Lazarski, Christopher A., et al.
Publicado: (2006)

Prediction of MHC class II binding peptides based on an iterative learning model
por: Murugan, Naveen, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_tp3f7imnvc50t1pjtgdfjgd5di